Repairing heart muscle with stem cells

Trial run for tissue engineered 'heart patch'

For the first time, engineered heart muscle (EHM) from human induced pluripotent stem cells (iPSCs) will be used to treat patients with heart failure.

After regulatory approval, recruitment of the first patient for the first-in-class, first-in-patient BioVAT-HF early clinical trial has started in Göttingen, Germany. The trial is sponsored by the University Medical Center Göttingen and funded by the German Center for Cardiovascular Research (DZHK) and the Repairon GmbH. Additional participating centers include the University Medical Center Schleswig-Holstein in Lübeck and the Heart- and Diabetes Center of the Ruhr University of Bochum in Bad Oeynhausen.

Engineered Heart Muscle (EHM)
Source: UMG

Heart failure affects 60 million people worldwide. With current treatment and medical care, one out of five patients with heart failure will die within 12 months – there is no cure. This means that half of those diagnosed with heart failure today will not be alive in 5 years. The BioVAT-HF-DZHK20** Phase I/II clinical trial comes after 25 years of compre-hensive preclinical development, and is the first to investigate whether the implantation of a heart muscle patch, grown in a laboratory from stem cells, can safely and effectively repair the failing heart.

Approval of the BioVAT-HF-DZHK20 multicenter trial was granted by the Paul-Ehrlich-Institute at the end of 2020. The trial is scheduled to enroll 53 patients with advanced heart failure.

Additional information on the trial can be found on (Identifier: NCT04396899)

Source: University Medical Center Göttingen


Read all latest stories

Related articles


Cardiology research

How hypertension leads to atherosclerosis

Research scientists at Aarhus University and Aarhus University Hospital have investigated the mechanisms by which hypertension leads to arterial damage and atherosclerosis. The results may facilitate…



High blood pressure causes atrial fibrillation

The first evidence from genetic data that high blood pressure is causally associated with the most common heart rhythm disorder is published in the European Journal of Preventive Cardiology, a…


Coronavirus and the heart

Covid-19 infection raises risk of dying after a cardiac arrest

Covid-19 patients who suffer a cardiac arrest either in or out of hospital are far more likely to die than patients who are not infected with the coronavirus. In particular, women have the highest…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter